2354. Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for rifampin-resistant or treatment-intolerant TB disease

BACKGROUND: Tuberculosis (TB) remains a leading infectious cause of death and morbidity globally. Rifampin-resistance or intolerance requires prolonged treatment using less effective, more toxic regimens. Recent trials demonstrated that the all-oral six-month “BPaL” regimen, Bedaquiline, Pretomanid...

Descripción completa

Detalles Bibliográficos
Autores principales: Haley, Connie A, Ashkin, David, Peloquin, Charles A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752306/
http://dx.doi.org/10.1093/ofid/ofac492.161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752306/
http://dx.doi.org/10.1093/ofid/ofac492.161

Ejemplares similares